OnCo
trialsTrialPositive

CheckMate 649

The trial that added immunotherapy to first-line stomach cancer chemotherapy; at five years, 16% of patients with PD-L1-rich tumours were alive versus 6%.

Largest phase 3 in gastric cancer. PD-L1 CPS ≥5: OS 14.4 vs 11.1 months (HR 0.71), 5-year OS 16% vs 6% (Annals of Oncology 2026). All randomised: OS 13.7 vs 11.6 months (HR 0.79). FDA approved for all patients (2021); EMA and many guidelines restrict to CPS ≥5 because benefit in CPS <1 is unproven.

Setting
First-line HER2-negative advanced gastric/GEJ/oesophageal adenocarcinoma: nivolumab + chemotherapy vs chemotherapy
Phase
Phase 3
Sponsor
BMS
Registry
Headline result
CPS ≥5: OS 14.4 vs 11.1 months (HR 0.71); 5-year OS 16% vs 6%.
Reported
2020
Enrolled
1581
Replication
Replicated by KEYNOTE-859 (pembrolizumab), RATIONALE-305 (tislelizumab), and ORIENT-16 (sintilimab).

Outcomes

2top
In plain words
What these results mean for people, not percentages
1,581 people took part
Overall survival, PD-L1 CPS ≥5primarysurvival endpoint
  • Median 14.4 vs 11.1 months with Nivolumab + chemotherapy compared with Chemotherapy; about 3.3 months longer for half the group.
  • A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
  • Put another way, the treated group had about 29 percent lower chance of the event at any given time (hazard ratio 0.71, likely range 0.61 to 0.81).
Overall survival at 5 years, CPS ≥5survival endpoint
  • 16 vs 6 out of 100 alive at 5 years with Nivolumab + chemotherapy compared with Chemotherapy; 10 more per 100.
  • Roughly one extra person helped for every 10 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
Be careful
  • Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
  • These results apply to the people the trial enrolled: First-line HER2-negative advanced gastric/GEJ/oesophageal adenocarcinoma: nivolumab + chemotherapy vs chemotherapy. People in a different situation may not see the same effect.
  • The trial selected people by a biomarker (HER2); the result should not be assumed for people whose cancer does not have it.

Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.

1,581 participants enrolled.

Overall survival, PD-L1 CPS ≥5primary
HR 0.71 (0.61–0.81)
Nivolumab + chemotherapy
14.4 mo
Chemotherapy
11.1 mo
Source
Overall survival at 5 years, CPS ≥5
Nivolumab + chemotherapy
16 mo
Chemotherapy
6 mo
Source
EndpointArmnValueHR (95% CI)pSource
Overall survival, PD-L1 CPS ≥5primaryNivolumab + chemotherapy47314.4 months0.71 (0.61–0.81)link
Chemotherapy48211.1 months
Overall survival at 5 years, CPS ≥5Nivolumab + chemotherapy16 percentlink
Chemotherapy6 percent
Replication
Replicated by KEYNOTE-859 (pembrolizumab), RATIONALE-305 (tislelizumab), and ORIENT-16 (sintilimab).

Connected

11top

Pages like this

not linked directly; found by shared links